Skip to content

ACCENTIA BIOPHARMACEUTICALS INC

CIK 0001310094

← back to feed
Revenue (TTM)
$4.42M
+2.5% YoY FY Nov 2012
Net Income (TTM)
—
FY Nov 2012
EPS Diluted (TTM)
−$0.07
FY Nov 2012
Gross Margin
36.9%
FY Nov 2012
Operating Margin
-277.3%
FY Nov 2012
Net Margin
—
FY Nov 2012
Free Cash Flow (TTM)
−$6.41M
FY Nov 2012
Cash
$129.17K
FY Nov 2012
Total Debt
$23.65M
FY Nov 2012
Shares Outstanding
89.76M sh
FY Nov 2012

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings